Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07332000 · ClinicalTrials.gov registry record · Phase 2
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
A Phase 2 study of Prostate Cancer (Adenocarcinoma) and Prostate Cancer Patients Treated by Radiotherapy, sponsored by Candel Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 7
- Study locations
NCT07332000: Recruiting Phase 2 study of Prostate Cancer (Adenocarcinoma) and Prostate Cancer Patients Treated by Radiotherapy, sponsored by Candel Therapeutics.
NCT07332000 is a Phase 2 study of Prostate Cancer (Adenocarcinoma) and Prostate Cancer Patients Treated by Radiotherapy that is actively recruiting participants, run by Candel Therapeutics. The registered enrollment target is 45 participants, below the 127-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (65% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07332000, a Phase 2 study of Prostate Cancer (Adenocarcinoma) and Prostate Cancer Patients Treated by Radiotherapy, is actively recruiting participants, sponsored by Candel Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 7
- Study locations
Study Summary
Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation therapy (EBRT).
Primary Outcome
Evaluation of shedding of aglatimagene besadenovec viral genomes in urine, blood, and semen samples using validated bioassays over time.
Conditions Studied
Interventions
- BIOLOGICAL aglatimagene besadenovec + valacyclovir
- RADIATION External Beam Radiation Therapy (EBRT)
Study Locations (7)
Colorado
- Colorado Clinical Research - Lakewood
- Urology Associates - Littleton
Arizona
- Academic Urology and Urogynecology of Arizona - Peoria
Maryland
- Chesapeake Urology Research Associates - Towson
Nevada
- Sheldon Freedman, MD Ltd. - Las Vegas
New Jersey
- Summit Health - Saddle Brook
South Carolina
- START Carolinas - Myrtle Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-10-30 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
What NCT07332000 shows while recruiting
NCT07332000 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 127-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (65% lower).
The record links to 2 conditions, with Prostate Cancer (Adenocarcinoma) appearing as the primary indexed condition, and to 2 interventions - of which aglatimagene besadenovec + valacyclovir is the first listed.
NCT07332000 lists 7 locations in 6 states (Colorado, Arizona, Maryland).
Frequently Asked Questions
What is clinical trial NCT07332000 about?
NCT07332000 is a clinical study titled "A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec". Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation therapy (EBRT).
What is the current status of trial NCT07332000?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2025-10-30. Estimated completion is 2026-08.
What conditions does trial NCT07332000 study?
This clinical trial studies the following conditions: Prostate Cancer (Adenocarcinoma), Prostate Cancer Patients Treated by Radiotherapy.
What interventions are being tested in trial NCT07332000?
The interventions under investigation include: aglatimagene besadenovec + valacyclovir (BIOLOGICAL), External Beam Radiation Therapy (EBRT) (RADIATION).
Who is sponsoring clinical trial NCT07332000?
This trial is sponsored by Candel Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07332000 being conducted?
This trial has 7 study locations across Arizona, Colorado, Maryland, Nevada, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer (Adenocarcinoma)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07332000's enrollment target sits among peer trials
45 11th of 13 higher than 3 of 13 other Prostate Cancer (Adenocarcinoma) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer (Adenocarcinoma) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
RECRUITING · Phase 2
-
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
RECRUITING · Phase 2
-
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
RECRUITING · Phase 2
-
Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C)
ACTIVE NOT RECRUITING · Phase 2
-
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI